CompletedNot Applicable

Can Resistance Enhance Selection of Treatment? (CREST)

Australia338 participantsStarted 2001-03-01

Plain-language summary

To compare two commercially available platforms for assessment of HIV drug resistance to determine which provides superior virological results. We hypothesise that one test will be significantly superior to the other.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HIV infected patients taking combination antiretroviral therapy, with plasma HIV RNA\> 2000copies/mL, who were willing to change ARVs and who provided informed consent. Exclusion Criteria: * Patients who were ARV naïve, who were experiencing an acute illness or judged to be unable to comply with the protocol requirements.

What they're measuring

The comparison between randomly assigned study arms in the mean area under the curve plasma HIV RNA at 48 weeks.

Timeframe: at 48 weeks follow-up

Trial details

NCT IDNCT00262717

SponsorKirby Institute

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2006-01-30

View on ClinicalTrials.gov More HIV Infection trials